GlassScriptPhysician profile
Alejandro V Natividad
NPI 1467436014
$10,841.56
in general payments reported to CMS, 2019-2025
32 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $1,157 · 2021: $4,399 · 2022: $1,590 · 2023: $948 · 2024: $217 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,350.09 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $2,441.18 | 2019-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $715.76 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $664.20 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $513.94 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $505.63 | 2020-2023 | |
| Tris Pharma INC | $393.89 | 2022-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $266.60 | 2019-2021 | |
| Alkermes, INC. | $237.92 | 2019-2022 | |
| Abbvie INC. | $189.06 | 2019-2023 | |
| Biogen, INC. | $162.54 | 2019-2023 | Tysabri, Vumerity |
| Kyowa Kirin, INC. | $160.36 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $154.33 | 2019-2023 | |
| Lundbeck LLC | $147.17 | 2019-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $137.09 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $85.04 | 2019-2020 | |
| Allergan, INC. | $83.19 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.84 | 2022 | |
| Ironshore Pharmaceuticals INC. | $59.26 | 2022-2023 | Jornay Pm |
| Acorda Therapeutics, INC | $56.57 | 2019-2021 | |
| Harmony Biosciences LLC | $50.55 | 2022 | |
| Ucb, INC. | $50.49 | 2019-2021 | |
| Pfizer INC. | $49.57 | 2023 | |
| Genzyme Corporation | $45.02 | 2019-2021 | |
| Lilly USA, LLC | $44.22 | 2020-2023 | Emgality, Reyvow |
| Avanir Pharmaceuticals, INC. | $43.90 | 2019-2021 | |
| Genentech USA, INC. | $41.78 | 2022 | |
| Emd Serono, INC. | $37.60 | 2019 | |
| Amneal Pharmaceuticals LLC | $31.35 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $24.85 | 2021 | |
| Shire North American Group INC | $17.06 | 2019 | |
| Sk Life Science, INC. | $16.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Natividad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.